PR Newswire·3 min read·hard
Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 Congress
✦AI Summary
Argo Biopharma is set to present updated Phase II clinical trial results for its siRNA therapeutic, BW-20805, at the EAACI 2026 Congress. The drug targets hereditary angioedema (HAE) and has shown sustained efficacy in reducing attacks.
Why it matters
Advancements in siRNA therapeutics offer potential long-term prophylactic treatment options for patients with rare, life-threatening genetic conditions.
-Poster Presentation at the Thematic Poster Session-
healthscience
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 95%
The content is a factual report based on a corporate press release regarding clinical trial progress.
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in